Skip to main content

CCTG Publications

CCTG Publications

Canadian Cancer Trials Group Publications

As information about published study results becomes known, it will be available via the links below and announced in the CCTG Connection Newsletter. Both Canadian Cancer Trials Group and Intergroup led trials for which there has been at least one publication are included. 

If you do not find a particular study, this is likely because the final results are not yet available since many of our studies follow the health of participants for several years. Please refer to the study protocol, informed consent document or http://www.clinicaltrials.gov for further information about when the final study results are likely expected. Share this information with all investigators at your institution and the study participants at your centre so they may be informed of these results. Please ensure all local policies regarding dissemination of clinical trial results to staff and patients are followed. 

We are indebted to trial participants, physicians and other health care professionals who have contributed to the successful completion of hundreds of Canadian Cancer Trials Group trials.

For the most recent conference presentations and abstracts please visit Conference Presentations >

Publications

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU) (ONLINE)Journal of Clinical Oncology

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021) (ONLINE)Cancer Treatment and Research Communications

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021) (ONLINE)Cancer Treatment and Research Communications

Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White PaperCurrent Oncology

A phase 1 study of R-GDP–venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18)Blood Neoplasia

Effects of a structured exercise program on motivational outcomes in patients with colon cancerJNCI: Journal of the National Cancer Institute

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial (ONLINE)Annals of Oncology

Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial (ONLINE)Journal of Clinical Oncology

The final analysis of the HN9 trial shows that new immunotherapy treatment did not improve event free survival

HN9 final analysis shows that new immunotherapy treatment did not improve event free survival

Final results from the CCTG HN.9 (EORTC 1740-HNCG) were presented at ASCO 2026, highlighting the challenges of reducing treatment intensity while maintaining outcomes for oropharyngeal cancer patients .

More >>
 
PR21 Secondary Analysis Explores Treatment Sequencing in Advanced Prostate Cancer Trial

PR21 Secondary Analysis Explores Treatment Sequencing in Advanced Prostate Cancer

Results from a pre-planned secondary analysis of the PR21 PLUDO trial were presented at ASCO 2026—providing insight into treatment sequencing for patients with metastatic castration-resistant prostate cancer (mCRPC). 

More >>
 
Dr Nappi on stage at ASCO 2026 presenting interim results for CCTG trial

A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors

The interim results of the GCC.1 (S1823) study were presented at ASCO 2026 during the Genitourinary Cancer Session. The study focuses on patients with early-stage germ cell tumors and the blood biomarker microribonucleic acid (miRNA) 371a-3p (called miR371). The presence of miR371 may allow clinicians to identify patients at higher risk of relapse earlier and more accurately than current monitoring approaches.

More >>
 
Adjuvant durvalumab in completely resected non-small-cell lung cancer

The BR.31 lung cancer trial publication in the Journal of Clinical Oncology

The results of the BR.31 global Phase III study, testing adjuvant durvalumab in patients with completely resected non–small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.

More >>